CLINICAL TRIALS AND RESEARCH
87
$ 5.2 MILLION
Total cardiovascular research grants – Dallas and Fort Worth sites ( FY22 )
Fiscal year 2022 included many new and impressive clinical trials and studies . Activity increased compared to the prior fiscal year when the pandemic provided numerous challenges for investigators at the Dallas and Fort Worth research sites . Both sites participated in a variety of research projects through Baylor Scott & White Research Institute and other programs , with several of these projects receiving recognition for top enrollment and several medical leaders continued with clinical studies evaluating treatment options targeting COVID-19 .
CLINICAL TRIALS AND RESEARCH
Nationally recognized top enrolling studies during fiscal year 2022
BREATHE – Ranked # 1 nationwide ALL-IN – Ranked # 1 nationwide
SPYRAL ON – Ranked # 1 nationwide ( enrollment and randomization )
SPYRAL OFF – Ranked # 1 nationwide SPYRAL DYSTAL – Ranked # 1 nationwide DeLIVER STUDY – Ranked # 2 nationwide AGENT™ – Ranked # 2 nationwide SHORE – Ranked # 2 nationwide ARRAY-797-301 - Ranked # 3 nationwide Helios-A – Ranked # 3 nationwide NEUROS - Ranked # 4 nationwide TARGET – Ranked # 4 nationwide GUARDIAN Registry – Ranked # 5 worldwide Aries HM3 Study – Ranked # 7 worldwide Guide-HF – Ranked # 8 North America
For a complete listing of the clinical trials and the principal investigators : BSWHealth . com / research / clinical-trials
SOLTERO CARDIOVASCULAR RESEARCH CENTER : OPERATIONAL EXCELLENCE IN CARDIOVASCULAR RESEARCH
A cornerstone research organization for the Dallas location , Soltero Cardiovascular Research Center ( SCRC ), a part of Baylor Scott & White Research Institute , and through Baylor Scott & White Heart and Vascular Institute , during fiscal year 2022 , SCRC participated in more than 60 clinical trials and research studies .
Founded in 1987 , SCRC ’ s goal is to bring clinically relevant cardiology research studies to Baylor Scott & White Health to improve patients ’ lives by understanding , preventing and even reversing heart disease . Recognized as an innovative research center conducting high-quality studies , SCRC maintained a strong national presence with several studies recognized for their top enrollment during fiscal year 2022 .
In addition , SCRC director , Cara East , MD , FAPCR , FACP , FACC , continues her role as principal investigator in numerous studies while providing guidance and operational oversight to several principal investigators .
Widely published , Dr . East co-authored and contributed to several journal articles in fiscal year 2022 including :
• East C , Bass K , Mehta A , Rahimighazikalayed G , Zurawski S , and Bottiglieri T . Alirocumab and Lipid Levels , Inflammatory Biomarkers , Metabolomics , and Safety in Patients Receiving Maintenance Dialysis : The ALIrocumab in DIALysis Study ( A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen ). Kidney Medicine . Volume 4 , Issue 7 , 100483 ( May , 2022 ).
• Pfeffer MA , Claggett B , Lewis EF , East C , Braunwald E , et . al . Angiotensin receptorneprilysin inhibition in acute myocardial infarction . PARADISE-MI Investigators and Committees . New England Journal of Medicine . 2021 November 11 ; 385 ( 20 ): 1845-1855 .
Baylor Scott & White Heart and Vascular Hospital | Clinical Trials and Research